Paradoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphoma

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Bhalla, Savita ^a   Evens, Andrew M ^b   Prachand, Sheila ^a   Schumacker, Paul T ^a   Gordon, Leo I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABEXINOSTAT; BENZOFURAN DERIVATIVE; HIF1A PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

AUTOPHAGY; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; LARGE CELL LYMPHOMA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; AUTOPHAGY; BENZOFURANS; CELL SURVIVAL; DRUG SYNERGISM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOMA, LARGE B-CELL, DIFFUSE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84894247579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081333     Document Type: Article

References (65)

1. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92: 5510-5514. doi:10.1073/pnas.92.12.5510. PubMed: 7539918.
2. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH et al. (2001) Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J 15: 1312-1314. PubMed: 11344124.
3. Huang LE, Gu J, Schau M, Bunn HF (1998) Regulation of hypoxiainducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95: 7987-7992. doi:10.1073/pnas.95.14.7987. PubMed: 9653127.
4. Salceda S, Caro J (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redoxinduced changes. J Biol Chem 272: 22642-22647. doi:10.1074/jbc.272.36.22642. PubMed: 9278421.
5. Rankin EB, Giaccia AJ (2008) The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678-685. doi:10.1038/cdd.2008.21. PubMed: 18259193.
6. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396. PubMed: 10691731.
7. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835. PubMed: 10582706.
8. Evens AM, Schumacker PT, Helenowski IB, Singh AT, Dokic D et al. (2008) Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol 141: 676-680. doi:10.1111/j.1365-2141.2008. 07093.x. PubMed: 18422776.
9. Ganjoo KN, Moore AM, Orazi A, Sen JA, Johnson CS et al. (2008) The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol 134: 381-387. doi:10.1007/s00432-007-0294-x. PubMed: 17694324.
10. Cardesa-Salzmann TM, Colomo L, Gutierrez G, Chan WC, Weisenburger D et al. (2011) High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica 96: 996-1001. doi:10.3324/haematol.2010.037408. PubMed: 21546504.
11. Kim MK, Suh C, Chi HS, Cho HS, Bae YK et al. (2012) VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Sci 103: 497-503. doi:10.1111/j.1349-7006.2011.02168.x. PubMed: 22129133.
12. Larouche JF, Berger F, Chassagne-Clément C, Ffrench M, Callet-Bauchu E et al. (2010) Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 28: 2094-2100. doi:10.1200/JCO.2009.24.5860. PubMed: 20308668.
13. Belozerov VE, Van Meir EG (2005) Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 16: 901-909. doi:10.1097/01.cad. 0000180116.85912.69. PubMed: 16162966.
14. Melillo G (2006) Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4: 601-605. doi:10.1158/1541-7786.MCR-06-0235. PubMed: 16940159.
15. Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12: 853-859. doi:10.1016/j.drudis.2007.08.006. PubMed: 17933687.
16. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y et al. (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64: 6626-6634. doi:10.1158/0008-5472.CAN-04-0540. PubMed: 15374977.
17. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA et al. (2006) Class II histone deacetylases are associated with VHLindependent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66: 8814-8821. doi:10.1158/0008- 5472.CAN-05-4598. PubMed: 16951198.
18. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049. doi:10.1056/NEJMra0706596. PubMed: 18463380.
19. Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E et al. (2013) Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood 122: 2104-2113. doi:10.1182/blood-2013-02-485441. PubMed: 23913470.
20. Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE et al. (2010) Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 16: 554-565. doi:10.1158/1078-0432.CCR-09- 1937. PubMed: 20068080.
21. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784. doi:10.1038/nrd2133. PubMed: 16955068.
22. Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA et al. (2011) HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471: 74-79. doi:10.1038/nature09803. PubMed: 21368826.
23. Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5: 726-734. doi:10.1038/nrc1692. PubMed: 16148885.
24. Azad MB, Chen Y, Henson ES, Cizeau J, McMillan-Ward E et al. (2008) Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy 4: 195-204. PubMed: 18059169.
25. Tracy K, Macleod KF (2007) Regulation of mitochondrial integrity, autophagy and cell survival by BNIP3. Autophagy 3: 616-619. PubMed: 17786027.
26. Rikiishi H (2011) Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011: 830260
27. Chen S, Sang N (2011) Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol 2011: 197946.
28. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M et al. (2001) A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61: 439-444. PubMed: 11212227.
29. Evens AM, Sehn LH, Farinha P, Nelson BP, Raji A et al. (2010) Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 28: 1017-1024. doi:10.1200/JCO.2009.24.1893. PubMed: 20048181.
30. Bhalla S, Gordon LI, Singh A, Ahmed S, Dokic D et al. (2009) PX-478, a Novel Small Molecule Inhibitor of Hypoxia Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in Diffuse Large B Cell Lymphoma Cells. Blood 114: 1062-1063.
31. Lee K, Kim HM (2011) A novel approach to cancer therapy using PX-478 as a HIF-1alpha inhibitor. Arch Pharm Res 34: 1583-1585. doi:10.1007/s12272-011- 1021-3. PubMed: 22076756.
32. Palayoor ST, Mitchell JB, Cerna D, Degraff W, John-Aryankalayil M et al. (2008) PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 123: 2430-2437. doi:10.1002/ijc.23807. PubMed: 18729192.
33. Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J et al. (2009) The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 8: 947-958. doi:10.1158/1535-7163.MCT-08-0981. PubMed: 19372568.
34. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3: 233-244. PubMed: 15026543.
35. Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280: 145-153. doi:10.1016/j.canlet. 2008.11.012. PubMed: 19111391.
36. Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J et al. (2009) PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 15: 3354-3365. doi:10.1158/1078-0432.CCR-08-2365. PubMed: 19417023.
37. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275. doi:10.1038/20459. PubMed: 10353251.
38. Lim JH, Lee ES, You HJ, Lee JW, Park JW et al. (2004) Rasdependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 23: 9427-9431. doi:10.1038/sj.onc. 1208003. PubMed: 15543236.
39. Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A et al. (2009) The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem 284: 5332-5342. PubMed: 19098000.
40. Koshikawa N, Hayashi J, Nakagawara A, Takenaga K (2009) Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1alpha gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. J Biol Chem 284: 33185-33194. doi:10.1074/jbc.M109.054221. PubMed: 19801684.
41. Pouysségur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443. doi:10.1038/nature04871. PubMed: 16724055.
42. Hu YL, Jahangiri A, Delay M, Aghi MK (2012) Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res 72: 4294-4299. doi:10.1158/0008-5472.CAN-12-1076. PubMed: 22915758.
43. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z et al. (2007) The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 9: 218-224. doi:10.1038/ncb1537. PubMed: 17237771.
44. Giaccia A, Siim BG, Johnson RS (2003) HIF-1 as a target for drug development. Nat Rev Drug Discov 2: 803-811. doi:10.1038/nrd1199. PubMed: 14526383.
45. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732. doi:10.1038/nri1181. PubMed: 13130303.
46. Haeberle HA, Durrstein C, Rosenberger P, Hosakote YM, Kuhlicke J et al. (2008) Oxygen-independent stabilization of hypoxia inducible factor (HIF)-1 during RSV infection. PLOS ONE 3: e3352. doi:10.1371/journal.pone.0003352. PubMed: 18839041.
47. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL et al. (2012) Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci U S A 109: E2784-E2793. doi:10.1073/pnas.1018866109. PubMed: 22988108.
48. Eltzschig HK, Carmeliet P (2011) Hypoxia and inflammation. N Engl J Med 364: 656-665. doi:10.1056/NEJMra0910283. PubMed: 21323543.
49. Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P, Eltzschig HK (2007) Hypoxia inducible factor (HIF)-1 coordinates induction of Tolllike receptors TLR2 and TLR6 during hypoxia. PLOS ONE 2: e1364. doi:10.1371/journal. pone.0001364. PubMed: 18159247.
50. Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56. doi:10.1016/j.gde.2009.10.009. PubMed: 19942427.
51. Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M et al. (2008) Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 372: 892-897. doi:10.1016/j.bbrc.2008.05.150. PubMed: 18538129.
52. Zhong H, Semenza GL, Simons JW, De Marzo AM (2004) Upregulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 28: 88-93. doi:10.1016/j.cdp.2003.12.009. PubMed: 15068831.
53. Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441. doi:10.1016/S1535- 6108(04)00115-1. PubMed: 15144951.
54. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601. doi:10.1038/nm1052. PubMed: 15156201.
55. Khan O, La Thangue NB (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94. doi:10.1038/icb.2011.100. PubMed: 22124371.
56. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N et al. (2011) HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res 17: 3219-3232. doi:10.1158/1078-0432.CCR-11-0234. PubMed: 21474579.
57. Bonello S, Zähringer C, BelAiba RS, Djordjevic T, Hess J et al. (2007) Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 27: 755-761. doi:10.1161/01.ATV. 0000258979.92828.bc. PubMed: 17272744.
58. Schumacker PT (2011) SIRT3 controls cancer metabolic reprogramming by regulating ROS and HIF. Cancer Cell 19: 299-300. doi:10.1016/j.ccr.2011.03.001. PubMed: 21397853.
59. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C et al. (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545. PubMed: 10749120.
60. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N et al. (2003) Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 278: 31277-31285. doi:10.1074/jbc. M300763200. PubMed: 12764143.
61. Kim SY, Jeong E, Joung SM, Lee JY (2012) PI3K/Akt contributes to increased expression of Toll-like receptor 4 in macrophages exposed to hypoxic stress. Biochem Biophys Res Commun 419: 466-471. doi:10.1016/j.bbrc.2012.02.015. PubMed: 22424098.
62. Lum JJ, Bauer DE, Kong M, Harris MH, Li C et al. (2005) Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120: 237-248. doi:10.1016/j.cell.2004.11.046. PubMed: 15680329.
63. Ruan J (2011) Antiangiogenic therapies in non-Hodgkin's lymphoma. Curr Cancer Drug Targets 11: 1030-1043. doi:10.2174/156800911798073014. PubMed: 21933106.
64. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N et al. (2005) Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280: 32081-32089. doi:10.1074/jbc. M502876200. PubMed: 16027121.
65. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K et al. (2003) Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 278: 39422-39427. doi:10.1074/jbc.M305371200. PubMed: 12890675.